Clinical trial Recruiting at 1 site Observational Ages 18 and up

Evaluating heart issues in cancer patients

Official title: Evaluation and Management of Cardio Toxicity in Oncologic Patients

Run by Tel-Aviv Sourasky Medical Center · NCT02818517 · Data updated 2026-11-12

This study is trying to find out how to spot and manage heart problems in cancer patients and see if certain medications can help prevent these issues.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorTel-Aviv Sourasky Medical Center
Government
Drugs / interventionschemotherapy, radiation
Locations1 site (Tel Aviv)
StatusRecruiting
StartedAugust 1, 2016
Main results expectedNovember 30, 2030
Study endsDecember 31, 2031
Registry record updatedFebruary 2, 2022
Trial IDNCT02818517 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are cancer patients being evaluated in the cardio-oncology clinic at Tel Aviv Medical Center.

Probably not a fit

Patients who are not willing to provide informed consent or those who refuse to continue in the study may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on identifying and managing cardio toxicity in cancer patients, which can lead to serious heart problems. It aims to monitor patients through clinical evaluations, cardiac biomarkers, and echocardiograms to detect early signs of cardiac dysfunction. The study will create a registry of oncologic patients to better understand who is at increased risk for developing these heart issues. Additionally, it will explore the potential benefits of using ACE inhibitors and beta blockers in preventing cardiac dysfunction.

Why it matters

Potential benefit: If successful, this study could lead to improved management and prevention of heart problems in cancer survivors.

How similar studies have gone: Previous studies have suggested that interventions like ACE inhibitors and beta blockers may help prevent cardiac dysfunction in similar patient populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All patient evaluated in the cardio-oncology clinic in Tel Aviv MC

Exclusion Criteria:

* In the prospective Study - patients not sign an informed consent form.

Exclusion criteria experiment:

Patient reluctance to continue the study.

Where it's running

  • Tel Aviv Medical Center
    Tel Aviv, Israel
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.